척추 바이오로직스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 수술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Spine Biologics Market Growth & Trends:

The global spine biologics market size is estimated to reach USD 4.38 billion by 2030, expanding at a CAGR of 4.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

Spine Biologics Market Report Highlights:

• The spinal allografts segment dominated the market and accounted for 58.7% of the global revenue in 2024. This dominance can be attributed to the numerous benefits associated with the usage of allografts.
• The hospital segment dominated the market in 2024. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.
• North America dominated the market and accounted for a 48.2% share in 2024. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.
• Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Surgery
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Spine Biologics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Spine Biologics Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
• 4.4. Spinal Allografts
  • 4.4.1. Spinal Allografts Market, 2018 - 2030 (USD Billion)
    • 4.4.1.1. Machined Bones Allograft Market, 2018 - 2030 (USD Billion)
    • 4.4.1.2. Demineralized Bone Matrix Market, 2018 - 2030 (USD Billion)
• 4.5. Bone Graft Substitutes
  • 4.5.1. Bone Graft Substitutes Market, 2018 - 2030 (USD Billion)
    • 4.5.1.1. Bone Morphogenetic Proteins Market, 2018 - 2030 (USD Billion)
    • 4.5.1.2. Synthetic Bone Grafts Market, 2018 - 2030 (USD Billion)
• 4.6. Cell-based Matrix
  • 4.6.1. Cell-based Matrix Market, 2018 - 2030 (USD Billion)

Chapter 5. Spine Biologics Market: Surgery Business Analysis

• 5.1. Surgery Market Share, 2024 & 2030
• 5.2. Surgery Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Surgery, 2018 to 2030 (USD Billion)
• 5.4. Anterior Cervical Discectomy and Fusion (ACDF)
  • 5.4.1. Anterior Cervical Discectomy and Fusion (ACDF) Market, 2018 - 2030 (USD Billion)
• 5.5. Transforaminal Lumbar Interbody Fusion (TLIF)
  • 5.5.1. Transforaminal Lumbar Interbody Fusion (TLIF) Market, 2018 - 2030 (USD Billion)
• 5.6. Posterior Lumbar Interbody Fusion (PLIF)
  • 5.6.1. Posterior Lumbar Interbody Fusion (PLIF) Market, 2018 - 2030 (USD Billion)
• 5.7. Anterior Lumbar Interbody Fusion (ALIF)
  • 5.7.1. Anterior Lumbar Interbody Fusion (ALIF) Market, 2018 - 2030 (USD Billion)
• 5.8. Lateral Lumbar Interbody Fusion (LLIF)
  • 5.8.1. Lateral Lumbar Interbody Fusion (LLIF) Market, 2018 - 2030 (USD Billion)

Chapter 6. Spine Biologics Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 6.5. Outpatient Facilities
  • 6.5.1. Outpatient Facilities Market, 2018 - 2030 (USD Billion)

Chapter 7. Spine Biologics Market: Regional Estimates & Trend Analysis by Product

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. MEA
  • 7.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Spine Biologics Market: Regional Estimates & Trend Analysis by Surgery

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.5. Europe
  • 8.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.8. MEA
  • 8.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Spine Biologics Market: Regional Estimates & Trend Analysis by End Use

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework
    • 9.4.2.3. Competitive Insights
    • 9.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework
    • 9.4.3.3. Competitive Insights
    • 9.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework
    • 9.4.4.3. Competitive Insights
    • 9.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.5. Europe
  • 9.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework
    • 9.5.2.3. Competitive Insights
    • 9.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework
    • 9.5.3.3. Competitive Insights
    • 9.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework
    • 9.5.4.3. Competitive Insights
    • 9.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework
    • 9.5.5.3. Competitive Insights
    • 9.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework
    • 9.5.6.3. Competitive Insights
    • 9.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.7. Norway
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Regulatory Framework
    • 9.5.7.3. Competitive Insights
    • 9.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.8. Denmark
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Regulatory Framework
    • 9.5.8.3. Competitive Insights
    • 9.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.9. Sweden
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Regulatory Framework
    • 9.5.9.3. Competitive Insights
    • 9.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework
    • 9.6.2.3. Competitive Insights
    • 9.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Framework
    • 9.6.3.3. Competitive Insights
    • 9.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Framework
    • 9.6.4.3. Competitive Insights
    • 9.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.5. South Korea
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Framework
    • 9.6.5.3. Competitive Insights
    • 9.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.6. Australia
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Regulatory Framework
    • 9.6.6.3. Competitive Insights
    • 9.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Regulatory Framework
    • 9.6.7.3. Competitive Insights
    • 9.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.7. Latin America
  • 9.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework
    • 9.7.2.3. Competitive Insights
    • 9.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework
    • 9.7.3.3. Competitive Insights
    • 9.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.8. MEA
  • 9.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Regulatory Framework
    • 9.8.2.3. Competitive Insights
    • 9.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Regulatory Framework
    • 9.8.3.3. Competitive Insights
    • 9.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Regulatory Framework
    • 9.8.4.3. Competitive Insights
    • 9.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Regulatory Framework
    • 9.8.5.3. Competitive Insights
    • 9.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Stryker
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. NuVasive, Inc.
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Orthofix
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. DePuy Synthes (Johnson & Johnson)
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Exactech, Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Zimmer Biomet
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives